Skip to main content
Premium Trial:

Request an Annual Quote

Cellomics HCS Reader 2004 Upgrade for ArrayScan HCS, Cisbio s HTRF (Homogenous Time-Resolved Fluorescence) Reagents and Cyclic AMP Jumbo Kit, and CyBio s CyBi-Lumax flash HT


Cellomics said last month that it has launched the HCS Reader 2004 Upgrade, an upgrade package for its ArrayScan HCS instrumentation platform.

The upgrade consists of new software features and ease-of-use improvements, as well as a new shutterless, high-performance camera, which provides increased sensitivity and reliability, Cellomics said. In addition, the upgrade enables access to the V2 versions of Cellomics’ BioApplications, the company said.

Cisbio said last month that as of Jan. 3, all of its HTRF (homogenous time-resolved fluorescence) reagents, including those related to its service offering, will be referenced and delivered under the 384-well, low-volume (20 µL final volume) format.

Cisbio has also launched a new cyclic AMP jumbo kit (100,000 tests) particularly adapted to HTS requirements, the company said.

CyBio this week announced the availability of a new flash luminescence reader that incorporates the CyBi-Lumax flash HT 16-channel dispenser. The new reader is based on CyBio’s 1,536-well flash luminescence detection technology, but has increased throughput, CyBio said.


The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.